AlzeCure Receives EU Grant for Phase 2 Clinical Trial of NeuroRestore ACD856 for Alzheimer's Disease
STOCKHOLM, SWEDEN / ACCESS Newswire / February 17, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN ...
Hosted on MSN7h
AlzeCure Pharma secures €2.5m grant for Phase IIa trial of Alzheimer’s treatment
The trial will explore the effects of higher doses of ACD856, building on the drug’s established safety profile.
First Participant Randomized in AskBio European Phase 2 Gene Therapy Trial for Congestive Heart Failure
AB-1002 is an investigational gene therapy for the treatment of adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III heart failure symptoms GenePHIT is a clinical ...
PharmaTimes15d
Aplagon secures EUR 7 million for APAC phase 2a trials
Helsinki-based Aplagon has raised EUR 7 million to advance its APAC therapeutic for thrombo-inflammatory diseases into phase 2a clinical trials. Aki Prihti, CEO of Aplagon, said: “We’re delighted to ...
Business Wire1mon
Azafaros granted important regulatory designations and clearance by European authorities for global Phase 3 studies, to be initiated in 2025
Clinical Trial Application for global Phase 3 trials with nizubaglustat in GM1/GM2 gangliosidoses and Niemann-Pick Disease Type C approved in multiple European countries, anticipated to begin in ...
Aplagon Announces EUR 7 Million Financing to Advance its APAC Therapeutic for Thrombo-Inflammatory Diseases into Phase 2A Clinical Trials
Aplagon, a clinical stage biopharmaceutical company developing a first-in-class therapeutic for thrombo-inflammatory diseases, known as APAC, a heparin proteoglycan mimetic with antiplatelet and ...
Thiogenesis Receives Final EU Clearance of CTA to Initiate its Phase 2 Clinical Trial in MELAS
Detailed price information for Thiogenesis Therapeutics Corp (TTI-X) from The Globe and Mail including charting and trades.
AlzeCure Pharma: AlzeCure Receives EU Grant for Phase 2 Clinical Trial of NeuroRestore ACD856 for Alzheimer's Disease
STOCKHOLM, SWEDEN / ACCESS Newswire / February 17, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for di ...